The topline data revealed that sonelokimab provided "clinically meaningful and statistically significant benefit" across key metrics. According to the company, patients reported a notable decrease in pain levels, while diagnostic imaging confirmed a reduction in both inflammation and osteoblast activity. This activity is responsible for the abnormal bone formation characteristic of the disease. The drug works by inhibiting specific immune pathways that drive the progression of inflammation and ossification.

Investors responded aggressively to the clinical milestone, sending MoonLake shares up 6.5% to $20 during Monday's premarket session. The rally extends a period of significant growth for the stock, which had already gained 42% this year as of Friday's close. Analysts view the successful Phase 2 results as a critical validation of the company's therapeutic platform.

Strengthening the Balance Sheet

Alongside the clinical update, MoonLake announced an amendment to its debt facility with Hercules Capital. The company has drawn down $25 million from the facility, leaving roughly $400 million in non-dilutive capital available to support future funding needs. Management indicated these funds will ensure the continued development of its therapeutic pipeline without immediate share dilution.